Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Capecitabine Pregnancy and Breastfeeding Warnings

Capecitabine is also known as: Xeloda

Capecitabine Pregnancy Warnings

UK: Contraindicated AU, US: Use is not recommended AU TGA pregnancy category: D US FDA pregnancy category: D Comments: -This drug can cause fetal harm when administered to a pregnant woman. -Women of child bearing potential should be advised to avoid becoming pregnant while receiving treatment with this drug. -If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be advised of the potential hazard to the fetus. -This drug may cause degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids in males.

This drug and/or its metabolites have been shown to cross the placenta in animal studies. It was shown to be teratogenic and embryolethal when administered orally during organogenesis. Teratogenic findings included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilatation of cerebral ventricles. There are no controlled data in human pregnancy. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Capecitabine Breastfeeding Warnings

UK: Contraindicated AU, US: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comment: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide